Skip to main content
Caplight Logo









Nova In Silico

Nova In Silico

Private
LyonHealthcare & Life Scienceshttps://www.novainsilico.ai/

Last Round

Series A

Extension

Feb 16, 2021

Total Funding Raised

$11.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Nova In Silico is a health-tech company that develops a clinical trial simulation platform, jinkō, which uses AI and mechanistic disease models to predict drug efficacy and optimize clinical trial development.

Sector

Healthcare & Life Sciences

Verticals

Clinical Trials, Drug Discovery, Medical AI, Synthetic Data, Vertical SaaS

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting, Government Contracts

AI Layer

Infrastructure

Keywords

in silico clinical trialsclinical trial simulationmechanistic disease modelsquantitative systems pharmacologyQSPvirtual patientstrial design optimizationcomputational drug developmentAI drug developmentpatient digital twinmodeling and simulationM&Sdrug development softwareregulatory evidence supportsurrogate modelshealth technology assessmentHTA

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nova In Silico Comparables

Compare Nova In Silico with similar companies based on industry and business-model similarity.

Nova In Silico comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
QuantHealth
88%
InSilicoTrials Technologies
86%
Unlearn
81%

Nova In Silico Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionFeb 16, 2021
GrantJan 19, 2021
Series AJan 9, 2020

Nova In Silico Investors

Notable investors and investment history

Nova In Silico investors
InvestorRounds
BpifranceGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 22, 2026

    Grew 16% QoQ, from 56 to 65 employees.

  • Jan 27, 2026

    Monthly visitors increased 154% from 2K to 5.2K.

Nova In Silico Filings

Explore SEC and related filing metadata, where available.

Nova In Silico filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nova In Silico's valuation, stock price, and market status.

Is Nova In Silico a public or private company?

Nova In Silico is a private company.

What is the current stock price of Nova In Silico?

Nova In Silico is a private company with no public stock price. No recent secondary market data is available.

How much is Nova In Silico worth (valuation)?

Valuation information for Nova In Silico is not publicly available.

Can I buy Nova In Silico stock?

Nova In Silico shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Nova In Silico's last funding round?

Nova In Silico's most recent funding round was Series A Extension on February 16, 2021.

Who are the main investors in Nova In Silico?

Key investors in Nova In Silico include Bpifrance.

Will Nova In Silico IPO soon?

No public IPO plans have been announced for Nova In Silico.

How can I track Nova In Silico secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nova In Silico's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLyon
Employee Range64
Year Founded2010
Last FundingFeb 16, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?